)
Joseph M. Reisman is a partner in our San Diego office.
Dr. Reisman's practice involves patent prosecution and strategic counseling, chiefly for clients in the pharmaceutical, chemical, and biotechnology, industries, as well as patent litigation and appellate work involving various technologies. His practice allows him to utilize the technical training he received while earning a Ph.D. in Chemistry. His litigation experience is varied, and includes numerous complex patent infringement actions brought under the Hatch-Waxman Act, in which represented both defendants and plaintiffs. He has also authored numerous appeal briefs, and conducted oral argument on appeal at the Court of Appeals for the Federal Circuit. Dr. Reisman often represents manufacturers of generic and follow-on products, and has been a team leader in successfully earning early market entry of generic equivalents of many well-known products, including Lipitor (atorvastatin) and Valcyte (valganciclovir). Dr. Reisman regularly counsels his clients as they prepare their Abbreviated New Drug Applications (ANDAs) and provides strategic advice with an eye toward successful patent litigation strategies, including settlement, always keyed to successful business outcomes.
Dr. Reisman also has extensive experience obtaining and enforcing complex patent portfolios, trade secret rights and other forms of intellectual property for his clients. He has extensive experience developing patent portfolios relating to pharmaceutical, biotechnology, specialty chemical, and water treatment technologies.
During the course of his graduate studies in biochemistry, Dr. Reisman was awarded "La Bourse Chateaubriand" by the French Ministry of Foreign Affairs and the French Embassy to the United States. Under that six-month grant, he continued his doctoral research (at the University of California, San Diego) on the structure and function of certain DNA-binding proteins, while working at the Université de Montpellier in Montpellier, France. After graduating from law school at the University of California, Berkeley, Dr. Reisman served for two years as a Law Clerk to the Honorable Alan D. Lourie, Circuit Judge, at the United States Court of Appeals for the Federal Circuit.
In every year since 2012, Dr. Reisman has been included on the list of The Best Lawyers in America, and has been selected as a “Life Science Star” by LMG Life Sciences. These recognitions range from the field of Patent Prosecution, Patent Advisory, Strategy, and Management, Patent Litigation and, more specifically, Hatch-Waxman Litigation. Since 2000, he has regularly served as an Adjunct Professor of Patent Law at the University of San Diego, School of Law. He is also an active member of the Federal Circuit Bar Association. He has been, for several years, a member of the Association’s Board of Directors, and he currently serves as the Association’s President Elect.
Dr. Reisman joined the firm in 1998, and became a partner in 2002.
Clerk Experience
Law Clerk to the Honorable Alan D. Lourie, Circuit Judge
United States Court of Appeals for the Federal Circuit, 1996-1998
Dr. Reisman has received multiple awards and has been honored in both national and international forums for his legal accomplishments:
- Selected to the 2010 - 2022 editions of The Best Lawyers in America® for his work in Intellectual Property Litigation and Patent Law
- Recognized by The Legal 500 "United States" for Patent Litigation (2021)
- Named one of the "World's Leading Patent Professionals" in the Patent 1000 guide by Intellectual Asset Management (IAM) magazine for Prosecution. (2015-2021). In the 2018 guide, Dr. Reisman was described as being "extremely astute in counselling his pharmaceutical clients and narrowing their risk profile" and recognized for "leveraging his trial experience to prosecute patents that can withstand the rigours of litigation".
- Named Top Patent Challenger Attorney 2020 by Docket Navigator
- Named a "Life Science Star" in Legal Media Group (LMG) "Life Sciences". He has been recognized in all areas of the survey which include patent prosecution, patent advisory, strategy and management, general patent litigation/protection, and Hatch-Waxman litigation (2012 - 2018)
- Named by Legal Media Group (LMG) as one of the " World's Leading Patent Law Experts" (2015)
Quoted in, "The IP dangers in life sciences collaborations and how to avoid them," which was published by IAM. (June 2021)
Intellectual Property Issues Under the Trans-Pacific Partnership, Biosimilar Development, December 2015 (with Sheila Swaroop and Scott Seeley)
Southern District Rolls Out New Patent Local Rules, Association of Business Trial Lawyers - San Diego (ABTL) Report, Fall 2006 (with Fred Berretta)
Generic Biotech Products: Provisions in Patent and Drug Development Law, BioProcess International, October 2003 (with Arman H. Nadershahi)
Recent Developments in Intellectual Property Law, San Diego Business Journal, June 2000 (with Drew S. Hamilton)
Physicians and Surgeons as Inventors: Reconciling Medical Process Patents and Medical Ethics, Berkeley Technology Law Journal 10:355 (1995)
Speeches & Seminars
Revisiting Obviousness in the Hatch-Waxman Realm: Prior Art, Obvious-Type Double Patenting, Inherency by Anticipation and PTAB Findings, ACI Paragragh IV Disputes Conference, New York, NY, April 2016
Industry Panel, PatCon 4: The Annual Patent Conference, San Diego, CA, April 2014
Invalidity and Non-infringement Post-Microsoft v. i4i: Reaffirming of the ANDA Applicant's Pre-Litigation Obligations and Assertions, Sixth Annual Paragraph IV Disputes Conference, New York, NY, April 2012
Practitioners' Perspective on the Future of Patent Law, The University of San Diego School of Law's Second Annual Patent Law Conference, San Diego, CA, January 2012
Best Practices in Amicus Briefing (Moderator), The Federal Circuit Bar Association, Thirteenth Annual Bench & Bar Conference, Key Biscayne, FL, June 2011
Pharmaceutical Patent Protection in the United States, China Pharmaceuticals News' Patent Law Conference, WuXi, China, May 2010
Anti-Trust and Competition Law Issues Related to Generic Pharmaceutical Market Entry, The Eighth Generics, SuperGenerics & Patent Strategies Conference, London, England, May 2005.
Markman Hearings – Timing is Everything; When Are They Best Conducted, The Federal Circuit Bar Association's Fourth Bench & Bar Conference, San Diego, CA, June 2002.
From the Benchtop to the Bar, to the Bench: Protection and Defense of Chemical and Pharmaceutical Inventions, American Chemical Society, San Diego Section, San Diego, CA, November 2002.